DHC arrives at its June 10 print with a fresh analyst upgrade, a recovering stock price, and short interest that has quietly reversed lower — a setup that looks more constructive than the one described in last week's preview.
The most notable development since the June 3 note is the B. Riley target raise. John Massocca lifted his price target to $11 from $8.50 on June 9, maintaining a Buy rating — the second B. Riley target increase in four months and the most aggressive upward move from any covering analyst. Maxim Group also nudged its target to $10.50 from $10.00 on June 3. Both firms remain bullish, with targets that sit well above DHC's current $8.79. RBC Capital is the outlier, holding a Sector Perform with a $6.00 target — a meaningful discount to where the stock trades. The bull case centers on momentum and an improving senior housing backdrop. The bear case rests on persistent losses, a negative return on assets, and an EV/EBITDA multiple of 13.7x that looks stretched given the red ink.
Short interest has eased since last week's note described sellers methodically rebuilding. At 3.9% of free float — roughly 9.3 million shares — SI has fallen about 6% from its recent peak near 9.9 million shares in early May. The direction has reversed. Borrow conditions remain entirely unthreatening: availability is running at nearly 2,900% of estimated short interest, with a cost to borrow of just 0.44%. There is no squeeze pressure and no scarcity in the lending pool. Options positioning is similarly calm — the put/call ratio of 0.22 is fractionally below its 20-day average and near its 52-week low, signaling that traders are not paying up for downside protection into the print.
The stock has bounced. DHC closed at $8.79, up nearly 6% on Tuesday and 3.4% on the week — recovering the ground lost in the pullback flagged in the prior note. Healthcare REIT peers have also stabilised: LTC, OHI, VTR, and WELL all gained between 2% and 6% on the day, suggesting some sector-wide relief after recent weakness. Institutional ownership tells a supportive story too: BlackRock added 880,000 shares in the most recent filing period, JP Morgan Asset Management disclosed a new position of 2.2 million shares, and State Street added 2.3 million. Against that, Nomura trimmed 3 million shares.
The print will test whether the operational data — senior housing occupancy trends, NOI trajectory, and any commentary on the medical office portfolio — can begin to bridge the gap between DHC's exceptional momentum score and its persistently weak quality fundamentals.
See the live data behind this article on ORTEX.
Open DHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
